Surface Pharmaceuticals, an affiliated company of Imprimis Pharmaceuticals, has entered into a definitive stock purchase agreement with an affiliate of Flying L Partners to raise proceeds of about $20m in a private placement of its Series A preferred stock.
Zymeworks and Daiichi Sankyo have entered into a new license agreement, building upon their cross-licensing and collaboration agreement signed in 2016.
Eli Lilly and Company (Lilly) has agreed to acquire Canadian cancer drug developer AurKa Pharma from TVM Capital Life Science in a deal worth $575m.
Eli Lilly and Company (Lilly) has agreed to acquire Armo BioSciences, a US-based late-stage immuno-oncology company, for about $1.6bn in an all-cash deal.
Escient Pharmaceuticals has been launched with $40m Series A financing to advance G protein-coupled receptor (GPCR)-targeted drugs to address serious, unserved medical needs.
Forma Therapeutics and the University of Oxford have entered into a collaboration and license agreement to identify, validate and develop deubiquitinating enzyme (DUB) inhibitors for the treatment of neurodegenerative diseases.
Amneal Pharmaceuticals and Impax Laboratories have completed their business combination to form Amneal Pharmaceuticals.
InDex Pharmaceuticals Holding has developed a novel formulation of its lead drug candidate cobitolimod for oral administration, with targeted delivery to the lower part of the gastrointestinal tract.
Third Rock Ventures has launched Casma Therapeutics with a $58.5m investment to harness the cellular process of autophagy to develop breakthrough therapies.
Janssen Biotech has agreed to acquire US-based BeneVir Biopharm, a biopharmaceutical company focused on developing oncolytic immunotherapies for cancer, in a deal worth $1.04bn.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.